{"id":"W4385476635","doi":"10.1177/11795549231187264","title":"Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer","year":2023,"lang":"en","type":"review","venue":"Clinical Medicine Insights Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Ovarian cancer; Medicine; Monoclonal antibody; Oncology; Cancer; Chemotherapy; Cytotoxic T cell; Internal medicine; Drug resistance; Antibody; Immunology; Cancer research; Biology; In vitro","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002645287,0.0003549243,0.0007837636,0.001321535,0.0001441276,0.0005473911,0.0003776237,0.0004624808,0.003435147],"category_scores_gemma":[0.0003770582,0.0001528595,0.0004386296,0.001018414,0.0001513568,0.0005217628,0.0003970829,0.0008618125,0.001141793],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003219739,"about_ca_system_score_gemma":0.0005716373,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007391153,"about_ca_topic_score_gemma":0.001943078,"domain_scores_codex":[0.9999071,0.00001733906,0.00001717668,0.0000151951,0.00003431749,0.000008769804],"domain_scores_gemma":[0.9998884,0.00004970914,0.00002172721,0.000002806168,0.00002734755,0.00001005952],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001091075,0.00005584685,0.0001603003,0.02180849,0.0001165473,0.000152511,0.0000508435,0.0002498548,0.001650959,0.001317,0.01644498,0.9578836],"study_design_scores_gemma":[0.00004377852,0.0001885071,0.00104236,0.005337613,0.0002467374,0.001454242,0.00003731745,0.0001222288,0.0007327943,0.000872915,0.9899092,0.00001239645],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0002642528,0.9984604,0.00006617053,0.0001603571,0.00008439159,0.000005776674,0.00002097512,0.000006924483,0.000930732],"genre_scores_gemma":[0.0014483,0.9976163,0.0001060873,0.0001566286,0.00006006222,0.000005831573,0.00003955857,0.000001260249,0.0005659307],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.003435147,"threshold_uncertainty_score":0.01149166,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.3221679591626192,"score_gpt":0.5417869366401211,"score_spread":0.2196189774775019,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}